BIOMAT Database Logo BIOMAT Database Logo

[Efficiency of high-dose FEC chemotherapy for the mobilization of hematopoietic stem cells into peripheral blood]. 1997

L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
Service d'oncologie médicale, Université catholique de Louvain, Cliniques universitaires Saint-Luc, Bruxelles, Belgique.

The best regimen for mobilizing hematopoietic stem cells (HSC) into peripheral blood is not yet defined. The efficiency of FEC chemotherapy in the treatment of breast cancer is well established and the effects of FEC on HSC mobilization have been characterized. We tested the feasibility and the toxicity of a high-dose FEC regimen which may improve the mobilizing capacity of conventional FEC. Twenty patients with poor prognosis breast cancer received high-dose FEC and filgrastim 5 micrograms/kg. Three leukaphereses were performed on each patient for 3 consecutive days. Total numbers of CFU-GM and CD34+ cells were assessed, and a retrospective analysis was made. The numbers of CFU-GM/kg and CD34+ cells/kg collected (mean +/- standard error) were respectively 12.2 x 10(5) (+/- 2.4) and 14.6 x 10(6) (+/- 2.5). Extra-hematologic toxicity was negligible. Hematologic recovery after CTCb high-dose chemotherapy and HSC infusion was rapid. High-dose FEC is efficient for collecting HSC in peripheral blood. Extra-hematologic toxicity is weak and hematologic recovery after autograft is normal. Increased dosage of epirubicin and cyclophosphamide could allow a single leukapheresis collection of sufficient HSC from peripheral blood.

UI MeSH Term Description Entries
D007937 Leukapheresis The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor. Leukocytapheresis,Leukopheresis,Lymphapheresis,Lymphocytapheresis,Leukocytopheresis,Lymphocytopheresis,Lymphopheresis,Leukaphereses,Leukocytaphereses,Leukocytophereses,Leukophereses,Lymphaphereses,Lymphocytaphereses,Lymphocytophereses,Lymphophereses
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
Peripheral blood stem cell mobilization for high-dose chemotherapy.
April 1999, Journal of hematotherapy,
L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
Mobilization of hematopoietic stem cells into the peripheral blood.
December 2009, Expert review of hematology,
L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
February 2020, Clinical lymphoma, myeloma & leukemia,
L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
Hematopoietic growth factors for the mobilization of peripheral blood stem cells.
January 1993, Journal of hematotherapy,
L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
[Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies].
August 2004, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
Mobilization of hematopoietic stem cells (CFU-C) into the peripheral blood of man by endotoxin.
May 1977, Experimental hematology,
L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
[Mobilization of peripheral blood stem cells with conventional chemotherapy].
January 1996, Tumori,
L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
[Mobilization of hematopoietic stem cells in peripheral blood by leukapheresis].
January 1993, Beitrage zur Infusionstherapie = Contributions to infusion therapy,
L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
December 1997, Bone marrow transplantation,
L D'Hondt, and M André, and J L Canon, and T Guillaume, and C Doyen, and A M Feyens, and B Chatelain, and A Dromelet, and Y Humblet, and J Longueville, and M Symann
Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution.
April 2020, BMC cancer,
Copied contents to your clipboard!